Comparison of combination therapies of COVID_19

Phase 3

• Conditions: COVID-19.; COVID-19, virus identified; U07.1

• Registration Number: IRCT20200517047485N1
• Lead Sponsor: Arak University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 15 June 2020

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 108

Inclusion Criteria

Patients who are hospitalized in the ward and are considered to have a moderate form of COVID-19 (need to be admitted to the ward and not ICU hospital)
Patients who are satisfied with the study entry

Exclusion Criteria

The patient has a severe disease that requires Ribavirin
The patient need to be hospitalized in the ICU or intubation
The patient has a mild form of the disease that does not require hospitalization (patients with a history of outpatient treatment for COVID-19).
Patients with specific underlying disease and / or need to take specific medications

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Oxygen saturation following combination therapy for COVID-19. Timepoint: Daily examination of the patient during hospitalization. Method of measurement: pulse oxymetry.

Secondary Outcome Measures

Name	Time	Method
Treatment outcome (recovery rate). Timepoint: At the end of treatment and hospitalization. Method of measurement: physical examination and patient file.;Mortality rate. Timepoint: At the end of treatment and hospitalization. Method of measurement: patient file.;Complications of disease. Timepoint: At the end of treatment and hospitalization. Method of measurement: physical examination and patient file.